Do I have a Celebrex Case?

Shareholder Class Action Lawsuit Against Pfizer Inc.
December 16, 2004 07:36

Finkelstein, Thompson & Loughran has filed a securities fraud class action lawsuit in the United States District Court for the Southern District of New York, on behalf of investors who purchased or otherwise acquired the publicly-traded common stock of Pfizer, Inc. ("Pfizer" or the "Company") between November 1, 2000 and November 10, 2004, inclusive (the "Class Period").

The complaint alleges that, throughout the Class Period, defendants misrepresented and omitted material facts concerning the safety and marketability of Pfizer's Celebrex and Bextra products. Specifically, Plaintiff alleges that at all times during the Class Period, Defendants were aware of strong indicators that Celebrex and Bextra, drugs known as "Cox-2 Inhibitors," posed serious undisclosed health risks to consumers, that these undisclosed health risks would limit their marketability, and that the potential financial liability Pfizer faced from the harms these drugs caused posed a serious threat to the Company's finances. Nevertheless, Defendants concealed these facts from the investing public.

http://www.biospace.com/news_story.cfm?StoryID=18479120&full=1